Opicapone

Catechol-O-Methyltransferase Inhibitor — NERVOUS SYSTEM

Key facts

Opicapone is an onp drug in the Catechol-O-Methyltransferase Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2016. Its mechanism of action is classified as Catechol O-Methyltransferase Inhibitors. DrugCentral lists 3 molecular targets, including COMT, Comt and Comt. Recorded indications include Parkinson's disease.

• Approval status: onp (first approved 2016 by the EMA).
• Drug class: Catechol-O-Methyltransferase Inhibitor.
• Mechanism of action: Catechol O-Methyltransferase Inhibitors.
• Molecular targets: COMT, Comt and Comt (3 listed in DrugCentral).
• Indications: Parkinson's disease.
• ATC code: N04BX04 (Other dopaminergic agents).
• Molecular formula: C15H10Cl2N4O6; molecular weight 413.17 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Parkinson's disease

Mechanism & targets

• Mechanism of action (MoA): Catechol O-Methyltransferase Inhibitors
• Established pharmacologic class: Catechol-O-Methyltransferase Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
Catechol O-methyltransferase	COMT	inhibitor	Ki 9.00
Catechol O-methyltransferase	Comt	inhibitor	Ki 8.82
Catechol O-methyltransferase	Comt	inhibitor	Ki 8.82

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2020-06-29	PMDA	—	Ono Pharmaceutical Co., Ltd
2020-04-24	FDA	—	NEUROCRINE
2016-06-24	EMA	—	Bial

ATC classification

ATC code	Therapeutic hierarchy
N04BX04	NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Other dopaminergic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Dyskinesia	451.0
Hallucination	426.6
On and off phenomenon	165.8
Reduced facial expression	151.1
Dystonia	142.8
Muscle rigidity	139.9
Freezing phenomenon	135.2
Bradykinesia	134.8
Akinesia	132.6
Hallucination, visual	129.3
Hyperkinesia	117.7
Delusion	116.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Opicapone is on its molecule page.

• Molecular formula: C₁₅H₁₀Cl₂N₄O₆
• Molecular weight: 413.17 g/mol
• CAS number: —
• InChIKey: ASOADIZOVZTJSR-UHFFFAOYSA-N
• PubChem CID: 135565903

CC1=C(C2=NOC(=N2)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Opicapone used for?

DrugCentral lists the following indications for Opicapone: Parkinson's disease.

How does Opicapone work?

Opicapone is classified as Catechol O-Methyltransferase Inhibitors; its molecular targets in DrugCentral include COMT (inhibitor), Comt (inhibitor) and Comt (inhibitor).

When was Opicapone first approved?

Opicapone was first approved by the EMA in 2016.

What drug class does Opicapone belong to?

Opicapone is in the Catechol-O-Methyltransferase Inhibitor class.

What is the chemical formula of Opicapone?

Opicapone has the molecular formula C15H10Cl2N4O6 and a molecular weight of 413.17 g/mol.

Sources

• DrugCentral drug card 5143 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1089318 — compound record and bioactivity
• PubChem CID 135565903 — chemical identifiers
• DrugBank DB11632 — drug record
• FDA UNII Y5929UIJ5N — substance identity
• DailyMed: FDA labels for Opicapone — current prescribing information (label search)
• UniProt P21964 (COMT) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.